Edoardo Garbo

机构：The University of Texas MD Anderson Cancer Center, Harvard University, Dana-Farber Cancer Institute, Ospedale San Luigi Gonzaga, University of Turin · ORCID：0000-0003-2394-9895

发表论文 82 篇 · 总被引 270 次 · h-index 9

代表论文

• EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathway (2026 · Cancer Discovery · 被引 1)
• Tumor mutational burden as a predictor of immune-related adverse events in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors: a Brief Report (2026 · Journal of Thoracic Oncology)
• Effectiveness and safety of immunotherapy in advanced NSCLC with pericardial effusions: a global retrospective multicenter study (2026 · The Oncologist)
• PP01.48: Therapeutic Strategies and Immunotherapy Rechallenge Sensitivity After Progression Following Chemoradiation and Consolidation Durvalumab in Unresectable Stage III NSCLC: The POST-PACIFIC Study (2026 · Journal of Thoracic Oncology)
• PP01.20: Integrating Clinicopathologic and Genomic Features to Identify Patients at Risk of Earlier Progression to First-Line Osimertinib in EGFR-Mutant NSCLC (2026 · Journal of Thoracic Oncology)
• OA01.04: Tumor Mutational Burden as a Predictor of Immune-Related Adverse Events in Patients With Advanced Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors (2026 · Journal of Thoracic Oncology)